Literature DB >> 11227736

Possibility of age regulation of the natriuretic peptide C-receptor in human platelets.

D Giannessi1, M G Andreassi, S Del Ry, A Clerico, M G Colombo, N Dini.   

Abstract

Natriuretic peptide binding sites on platelets have been hypothesized to act as clearance receptors; however, there is no clear definition of the function of this receptor. The aim of the study was: 1) to characterize natriuretic peptide receptors in human platelets by original competition study; 2) to evaluate a possible age modulation of these binding sites, since a delayed clearance of ANP in the elderly has been observed. The binding of 125I-ANP to intact platelets was completely inhibited by h-ANP, h-BNP, h-CNP and c-ANP, the selective ligand of the clearance receptor. IC50 values were 0.089+/-0.029, 0.703+/-0.104 and 1.19+/-0.13, 3.84+/-0.04 nmol/l, mean+/-SE, respectively (p<0.001 for IC50 value of h-ANP compared to the other natriuretic peptides). This observation on the receptor selectivity of natriuretic peptides in human platelets provides new evidence for the presence of the clearance receptor on platelets. In control subjects the Kd was 34.6+/-4.0 pmol/l and Bmax 13.6+/-0.92 fmol/10(9) platelets (mean+/-SE), (no.=46, mean age 41.7+/-2.1 years). Bmax was significantly reduced in older subjects (no.=25, mean age 53.2+/-1.5 years) with respect to the younger group (no.=21, mean age 28.0+/-0.87 years): 11.4+/-1.1 vs 16.1+/-1.4 fmol/10(9) cells, p=0.0096, respectively; moreover, a significant inverse relationship between Bmax and the subject's age was observed. This observation suggests a possible reduction of the natriuretic peptide clearance with aging, associated to a significant increase of plasma levels of natriuretic peptides.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11227736     DOI: 10.1007/BF03343802

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  46 in total

Review 1.  Atrial natriuretic peptide: synthesis, release, and metabolism.

Authors:  H Ruskoaho
Journal:  Pharmacol Rev       Date:  1992-12       Impact factor: 25.468

2.  Platelet I1-imidazoline binding sites are decreased by two dissimilar antidepressant agents in depressed patients.

Authors:  J E Piletz; A E Halaris; D Chikkala; Y Qu
Journal:  J Psychiatr Res       Date:  1996 May-Jun       Impact factor: 4.791

3.  Calculating receptor number from binding experiments using same compound as radioligand and competitor.

Authors:  A DeBlasi; K O'Reilly; H J Motulsky
Journal:  Trends Pharmacol Sci       Date:  1989-06       Impact factor: 14.819

4.  The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system.

Authors:  N Matsukawa; W J Grzesik; N Takahashi; K N Pandey; S Pang; M Yamauchi; O Smithies
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-22       Impact factor: 11.205

5.  C-type natriuretic peptide and brain natriuretic peptide inhibit adenylyl cyclase activity: interaction with ANF-R2/ANP-C receptors.

Authors:  P Savoie; J de Champlain; M B Anand-Srivastava
Journal:  FEBS Lett       Date:  1995-08-14       Impact factor: 4.124

6.  Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis, and/or kaliuresis in humans.

Authors:  D L Vesely; M A Douglass; J R Dietz; W R Gower; M T McCormick; G Rodriguez-Paz; D D Schocken
Journal:  Circulation       Date:  1994-09       Impact factor: 29.690

7.  Influence of age and dose on the end-organ responses to atrial natriuretic peptide in humans.

Authors:  B A Clark; D Elahi; R P Shannon; J Y Wei; F H Epstein
Journal:  Am J Hypertens       Date:  1991-06       Impact factor: 2.689

8.  Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care.

Authors:  M R Cowie; A D Struthers; D A Wood; A J Coats; S G Thompson; P A Poole-Wilson; G C Sutton
Journal:  Lancet       Date:  1997-11-08       Impact factor: 79.321

9.  Metabolic clearance rate and plasma half life of alpha-human atrial natriuretic peptide in man.

Authors:  T G Yandle; A M Richards; M G Nicholls; R Cuneo; E A Espiner; J H Livesey
Journal:  Life Sci       Date:  1986-05-19       Impact factor: 5.037

10.  The platelet angiotensin II receptor in type I diabetes: studies in patients with and without nephropathy.

Authors:  M Makarious; M Pawlak; L V Campbell; V Timmermans; K Duggan; J A Charlesworth; G J Macdonald
Journal:  Eur J Clin Invest       Date:  1993-09       Impact factor: 4.686

View more
  8 in total

1.  Prevalence of maternal dietary iodine insufficiency in the north east of England: implications for the fetus.

Authors:  M S Kibirige; S Hutchison; C J Owen; H T Delves
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2004-09       Impact factor: 5.747

2.  Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction.

Authors:  Lisa C Costello-Boerrigter; Guido Boerrigter; Margaret M Redfield; Richard J Rodeheffer; Lynn H Urban; Douglas W Mahoney; Steven J Jacobsen; Denise M Heublein; John C Burnett
Journal:  J Am Coll Cardiol       Date:  2006-01-04       Impact factor: 24.094

3.  Plasma levels of natriuretic peptides and year-by-year blood pressure variability: a population-based study.

Authors:  J Kato; Y Kawagoe; D Jiang; K Kuwasako; S Shimamoto; K Igarashi; M Tokashiki; K Kitamura
Journal:  J Hum Hypertens       Date:  2017-03-02       Impact factor: 3.012

4.  Reference limits for N-terminal-pro-B-type natriuretic peptide in healthy individuals (from the Framingham Heart Study).

Authors:  Michael G Fradley; Martin G Larson; Susan Cheng; Elizabeth McCabe; Erin Coglianese; Ravi V Shah; Daniel Levy; Ramachandran S Vasan; Thomas J Wang
Journal:  Am J Cardiol       Date:  2011-08-23       Impact factor: 2.778

5.  Relation of N-terminal pro-B-type natriuretic peptide with diastolic function in hypertensive heart disease.

Authors:  Imran Uraizee; Susan Cheng; Chung-Lieh Hung; Anil Verma; James D Thomas; Michael R Zile; Gerard P Aurigemma; Scott D Solomon
Journal:  Am J Hypertens       Date:  2013-06-22       Impact factor: 2.689

6.  The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population.

Authors:  I Raymond; B A Groenning; P R Hildebrandt; J C Nilsson; M Baumann; J Trawinski; F Pedersen
Journal:  Heart       Date:  2003-07       Impact factor: 5.994

7.  Prognostic value of N-terminal pro-brain natriuretic peptide in elderly people with acute myocardial infarction: prospective observational study.

Authors:  L Lorgis; M Zeller; G Dentan; P Sicard; P Buffet; I L'Huillier; J C Beer; M Vincent-Martin; H Makki; P Gambert; Y Cottin
Journal:  BMJ       Date:  2009-05-06

8.  Plasma levels of natriuretic peptides and development of chronic kidney disease.

Authors:  Noriyuki Ogawa; Hiroshi Komura; Kenji Kuwasako; Kazuo Kitamura; Johji Kato
Journal:  BMC Nephrol       Date:  2015-10-24       Impact factor: 2.388

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.